CCCC 8-K 2026-09-25
C4 Therapeutics, Inc. (CCCC) 8-K dated 2026-09-25 — accession 0001628280-26-063497.
C4 Therapeutics, Inc. (CCCC) is a biotechnology company listed on US.
C4 Therapeutics, Inc. filed a 8-K on 2026-09-25. Accession 0001628280-26-063497.
This 8-K covers: Reg FD disclosure (Item 7.01), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported CCCC revenue for 2025-12-31 was $35.9M. Net income was -$105.0M. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. CCCC currently screens at market cap $425.7M.
Not investment advice. The CCCC SEC hub lists recent forms. The stock page is the research view.